Compare Microsoft (MSFT) vs TG Therapeutics Inc (TGTX) Price & Performance

Microsoft (MSFT) trades at $534.75, up 0.94% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.74 surpassing the $4.24 expectation. Revenue grew to $281.72 billion in 2025, and net income reached $101.83 billion, reflecting a robust 40.31% net margin. Analysts maintain a strong buy consensus with an average price target of $571.76, indicating potential upside from current levels.

The outlook for Microsoft remains positive, driven by AI leadership, Azure cloud growth, and solid cash flow generation. Key opportunities include expanding AI services and cloud market share, while risks involve high capital expenditures, competitive pressures, and macroeconomic volatility. The stock's valuation multiples, such as a P/E of 29.11, are elevated but supported by earnings growth and market position.

TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.

The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.